Crescent Biopharma (FRA:C68) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)


FRA:C68 Crescent Biopharma Inc FRA:C68
10 GF Score
Price €14.60
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma LT-Debt-to-Total-Asset?

Crescent Biopharma FRA:C68 10 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Crescent Biopharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

Crescent Biopharma's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.01). It may suggest that Crescent Biopharma is progressively becoming more dependent on debt to grow their business.

Crescent Biopharma  (FRA:C68) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Crescent Biopharma LT-Debt-to-Total-Asset Related Terms

Crescent Biopharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma LT-Debt-to-Total-Asset Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
LT-Debt-to-Total-Asset
1.05 0.01

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial 0.00 0.01 0.01 0.01 0.01
FRA:C68
10GF Score
Crescent Biopharma Inc FRA:C68
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma LT-Debt-to-Total-Asset Calculation

Crescent Biopharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=1.032/205.21
=0.01

Crescent Biopharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0.943/172.247
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
Crescent Biopharma (FRA:C68) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Crescent Biopharma and its competitors.
Is Crescent Biopharma's LT-Debt-to-Total-Asset too high?
Crescent Biopharma's current LT-Debt-to-Total-Asset is 0.01. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's LT-Debt-to-Total-Asset compare to KYTX and ZURA?
Crescent Biopharma's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current LT-Debt-to-Total-Asset of 0.01. The current LT-Debt-to-Total-Asset is 0.01. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for FRA:C68

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price